CLVT logo

Clarivate Plc (CLVT)

$2.29

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CLVT

Market cap

$1.47B

EPS

-0.52

P/E ratio

--

Price to sales

0.43

Dividend yield

--

Beta

1.384599

Price on CLVT

Previous close

$2.33

Today's open

$2.34

Day's range

$2.27 - $2.41

52 week range

$1.42 - $3.87

Profile about CLVT

CEO

Matti Shem Tov

Employees

12000

Headquarters

London,

Exchange

New York Stock Exchange

Shares outstanding

639904301

Issue type

Common Stock

CLVT industries and sectors

Technology

Software & IT Services

News on CLVT

Clarivate Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, Nov. 12, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration and final results of its previously announced cash tender offers (collectively, the "Offers") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding 3.875% Senior Secured Notes due 2028 (the "2028 Notes") for aggregate principal amount of up to $400,000,000 (the "2028 Notes Series Cap") and the outstanding 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for aggregate principal amount of up to $100,000,000 (the "2029 Notes Series Cap" and, together with the 2028 Notes Series Cap, each, a "Series Cap"), in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase") and any related documents (collectively with the Offer to Purchase, the "Tender Offer Documents"). Additionally, the Company has exercised its right to increase the aggregate principal amount of 2028 Notes and 2029 Notes accepted for purchase by 2% of the outstanding aggregate principal amount of each Series of Notes, and as a result, will accept for purchase $533,000,000 total aggregate principal amount of the Notes, with the tendered 2028 Notes and 2029 Notes accepted at a proration factor of approximately 67.9% and 45.5%, respectively.

news source

PRNewsWire • Nov 12, 2026

news preview

Clarivate's IPOne Connects Trusted Patent, Trademark and Litigation Intelligence to Claude

New Derwent patent and Darts-ip litigation connections give IP professionals access to curated patent and litigation intelligence alongside CompuMark trademark data   BARCELONA, Spain, Nov. 11, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that trusted patent and litigation intelligence from Clarivate is now available via Claude through IPOne, giving intellectual property (IP) professionals access to authoritative IP data within the AI workflows they already use. The IPOne Derwent patent and Darts-ip litigation data connectors are now listed on Anthropic's marketplace.

news source

PRNewsWire • Nov 11, 2026

news preview

Clarivate to Present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference on November 18

LONDON, Nov. 11, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Matti Shem Tov, Chief Executive Officer, and Michael Easton, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference, on Wednesday, November 18, 2026 at 2:00 pm Eastern Time. The live webcast can be accessed at https://kvgo.com/rbc/clarivate-plc-november-2026 and will be available for replay.

news source

PRNewsWire • Nov 11, 2026

news preview

Clarivate Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, Nov. 10, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yield with respect to the 2028 Notes and the 2028 Notes Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offers (collectively, the "Offers") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions set forth in the Offer to Purchase, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap").

news source

PRNewsWire • Nov 10, 2026

news preview

Clarivate PLC: Return Of Organic Growth Confirms Speculative Appeal

Clarivate PLC shares surged 40% after a solid Q3 and $600M life sciences divestment, reducing leverage and sharpening business focus. Clarivate now trades at modest valuations—2.6x sales, under 6x EBITDA, and about 3x earnings—despite only slight organic growth and persistent leverage risks. Forward guidance projects net leverage falling to 3.5–3.6x and free cash flow rising to $350–$400M by 2027, supporting a more manageable debt profile.

news source

Seeking Alpha • Nov 7, 2026

news preview

What Clarivate (CLVT) Said on Its Q3 Earnings Call

Clarivate NYSE: CLVT said it completed the sale of its Life Sciences & Healthcare segment ahead of schedule during the third quarter, leaving the company focused on its Academia & Government and Intellectual Property businesses. Management said the reshaped company has approximately $2 billion in revenue, with recurring organic revenue representing 93% of the total.

news source

MarketBeat • Nov 4, 2026

news preview

Clarivate Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LONDON, Nov. 4, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap") set forth in the Offer to Purchase.

news source

PRNewsWire • Nov 4, 2026

news preview

Clarivate Plc (CLVT) Q3 2026 Earnings Call Transcript

Clarivate Plc (CLVT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

— Improved recurring organic revenue growth driven by portfolio transformation  and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare segment — LONDON, Nov. 3, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2026. Executive Commentary Matti Shem Tov, Chief Executive Officer: "Third quarter results continued to improve across key metrics, including organic recurring revenue growth and the return to positive ACV growth in the Intellectual Property segment.

news source

PRNewsWire • Nov 3, 2026

news preview

Clarivate PLC (CLVT) Beats Q3 Earnings Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.18 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Clarivate Plc

Open an M1 investment account to buy and sell Clarivate Plc commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CLVT on M1